ReviewJournal of molecular and cellular cardiology2012
Heart of the matter: coronary dysfunction in metabolic syndrome.
Review in Journal of molecular and cellular cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 79 citations in OpenAlex.
- Trial
- Lipidomic Profiling and Biological Aging in Patients with Coronary Microvascular Dysfunction.Vascular health and risk management · 2026Article
- Coronary Microvascular Dysfunction in Ischaemic Heart Disease: Lessons From Large Animal Models.Basic & clinical pharmacology & toxicology · 2025Review
- Review
- Expanding landscape of coronary microvascular disease in co-morbid conditions: Metabolic disease and beyond.Journal of molecular and cellular cardiology · 2024Review
- The additive effect of metabolic syndrome on left ventricular impairment in patients with obstructive coronary artery disease assessed by 3.0 T cardiac magnetic resonance feature tracking.Cardiovascular diabetology · 2024Article
- Article
- Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment.Annals of medicine · 2023Article
- Interventions to Address Cardiovascular Risk in Obese Patients: Many Hands Make Light Work.Journal of cardiovascular development and disease · 2023Review
- Coronary microvascular dysfunction in heart failure patients.Frontiers in cardiovascular medicine · 2023Review
- The impact of obesity on the regulation of muscle blood flow during exercise in patients with heart failure with a preserved ejection fraction.Journal of applied physiology (Bethesda, Md. : 1985) · 2022Article
- Review
- Biological Potential of Polyphenols in the Context of Metabolic Syndrome: An Analysis of Studies on Animal Models.Biology · 2022Review
- Endothelial Progenitor Cells Dysfunctions and Cardiometabolic Disorders: From Mechanisms to Therapeutic Approaches.International journal of molecular sciences · 2021Review
- Particulate matter inhalation and the exacerbation of cardiopulmonary toxicity due to metabolic disease.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Mechanobiology of Microvascular Function and Structure in Health and Disease: Focus on the Coronary Circulation.Frontiers in physiology · 2021Review
- ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'.Cardiovascular research · 2020Review
- Chaiqi decoction ameliorates vascular endothelial injury in metabolic syndrome by upregulating autophagy.American journal of translational research · 2020Article
- Shaker-related voltage-gated KMicrocirculation (New York, N.Y. : 1994) · 2018Article
- Cardiovascular consequences of metabolic syndrome.Translational research : the journal of laboratory and clinical medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Metabolic syndrome (MetS) is a collection of risk factors including obesity, dyslipidemia, insulin resistance/impaired glucose tolerance, and/or hypertension. The incidence of obesity has reached pandemic levels, as ~20-30% of adults in most developed countries can be classified as having MetS. This increased prevalence of MetS is critical as it is associated with a two-fold elevated risk for cardiovascular disease. Although the pathophysiology underlying this increase in disease has not been clearly defined, recent evidence indicates that alterations in the control of coronary blood flow could play an important role. The purpose of this review is to highlight current understanding of the effects of MetS on regulation of coronary blood flow and to outline the potential mechanisms involved. In particular, the role of neurohumoral modulation via sympathetic α-adrenoceptors and the renin-angiotensin-aldosterone system (RAAS) are explored. Alterations in the contribution of end-effector K(+), Ca(2+), and transient receptor potential (TRP) channels are also addressed. Finally, future perspectives and potential therapeutic targeting of the microcirculation in MetS are discussed. This article is part of a Special Issue entitled "Coronary Blood Flow".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.